摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-chloro-4-hydroxy-7-methoxy-2H-chromen-2-one

中文名称
——
中文别名
——
英文名称
6-chloro-4-hydroxy-7-methoxy-2H-chromen-2-one
英文别名
6-chloro-4-hydroxy-7-methoxychromen-2-one
6-chloro-4-hydroxy-7-methoxy-2H-chromen-2-one化学式
CAS
——
化学式
C10H7ClO4
mdl
——
分子量
226.616
InChiKey
NNLNQUFCJQTEOD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    6-chloro-4-hydroxy-7-methoxy-2H-chromen-2-one 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 硫酸盐酸羟胺sodium ethanolate三乙胺 作用下, 以 四氢呋喃乙醇二氯甲烷二甲基亚砜 为溶剂, 反应 172.0h, 生成 3-(5-chloro-6-methoxybenzo[d]isoxazol-3-yl)propanenitrile
    参考文献:
    名称:
    [EN] 3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS
    [FR] ACIDE 3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOÏQUE UTILE EN TANT QU'INHIBITEUR DE LA KYNURÉNINE MONOOXYGÉNASE
    摘要:
    化合物的化学式(I),其中R1是杂环芳基,可以是未取代的或取代的,取代基可以是甲基、乙基、卤素或=O;R2是H、甲基或乙基;它们的盐是KMO抑制剂,可能在治疗各种疾病中有用,例如急性胰腺炎、慢性肾病、急性肾病、急性肾损伤、其他与全身性炎症反应综合征(SIRS)相关的疾病、亨廷顿病、阿尔茨海默病、脊髓小脑共济失调、帕金森病、艾滋病痴呆综合征、HIV感染、肌萎缩性侧索硬化(ALS)、抑郁症、精神分裂症、败血症、心血管休克、严重创伤、急性肺损伤、急性呼吸窘迫综合征、急性胆囊炎、严重烧伤、肺炎、广泛的外科手术、缺血性肠病、严重急性肝病、严重急性肝性脑病或急性肾功能衰竭。
    公开号:
    WO2016097144A1
  • 作为产物:
    描述:
    4-氯间苯二酚三氟化硼乙醚 、 sodium hydride 、 potassium carbonate溶剂黄146 作用下, 以 丙酮甲苯 、 mineral oil 为溶剂, 反应 120.5h, 生成 6-chloro-4-hydroxy-7-methoxy-2H-chromen-2-one
    参考文献:
    名称:
    [EN] 3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS
    [FR] ACIDE 3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOÏQUE UTILE EN TANT QU'INHIBITEUR DE LA KYNURÉNINE MONOOXYGÉNASE
    摘要:
    化合物的化学式(I),其中R1是杂环芳基,可以是未取代的或取代的,取代基可以是甲基、乙基、卤素或=O;R2是H、甲基或乙基;它们的盐是KMO抑制剂,可能在治疗各种疾病中有用,例如急性胰腺炎、慢性肾病、急性肾病、急性肾损伤、其他与全身性炎症反应综合征(SIRS)相关的疾病、亨廷顿病、阿尔茨海默病、脊髓小脑共济失调、帕金森病、艾滋病痴呆综合征、HIV感染、肌萎缩性侧索硬化(ALS)、抑郁症、精神分裂症、败血症、心血管休克、严重创伤、急性肺损伤、急性呼吸窘迫综合征、急性胆囊炎、严重烧伤、肺炎、广泛的外科手术、缺血性肠病、严重急性肝病、严重急性肝性脑病或急性肾功能衰竭。
    公开号:
    WO2016097144A1
点击查看最新优质反应信息

文献信息

  • DABCO-catalyzed one-pot three component synthesis of dihydropyrano[3,2-c]chromene substituted quinazolines and their evaluation towards anticancer activity
    作者:Sumathi Vodnala、A.K.D. Bhavani、Ramakrishna Kamutam、V.G.M. Naidu、Promila、Ch. Prabhakar
    DOI:10.1016/j.bmcl.2016.07.003
    日期:2016.8
    A facile DABCO promoted one-pot three component synthesis of a new series of C-C linked bis-heterocycle containing dihydropyrano[c]chromene as highly fused oxa-heteryl group at C-2 position of quinazoline was developed. Quinazoline-2-carbaldehyde, substituted 4-hydroxycoumarin and ethyl cyanoacetate were used as key components in the Knoevenagel-Michael addition reaction to get the titled compounds
    开发了一种简便的DABCO促进了一系列新的CC连接的双杂环的单锅三组分合成,该双环的双环含有二氢喃并[c]苯甲基作为喹唑啉C-2位的高度稠合的氧杂杂环基。喹唑啉-2-甲醛,取代的4-羟香豆素乙酸乙酯用作Knoevenagel-Michael加成反应的关键组分,得到标题化合物。筛选了这些化合物对MDA-MB 231和MDA-MB 453乳腺癌细胞系的抗癌活性。
  • 3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors
    申请人:GlaxoSmithKline Intellectual Property Development Limited
    公开号:US10273232B2
    公开(公告)日:2019-04-30
    The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
    本发明涉及一种式 (I) 的化合物 或其药学上可接受的盐,它们是犬尿酸单加氧酶(KMO)抑制剂,可用于治疗各种疾病,其中可包括但不限于以下疾病,例如急性胰腺炎、慢性肾脏病、急性肾脏病、急性肾损伤、与全身炎症反应综合征(SIRS)相关的其他疾病、亨廷顿氏病、阿尔茨海默病、脊髓小脑性共济失调、帕森氏病、艾滋病-痴呆综合征、艾滋病病毒感染、淀粉样变性脊髓侧索硬化症(ALS)、抑郁症、精神分裂症、败血症、心血管休克、严重创伤、急性肺损伤、急性呼吸窘迫综合征、急性胆囊炎、严重烧伤、肺炎、大面积外科手术、缺血性肠道、严重急性肝病、严重急性肝性脑病或急性肾功能衰竭。
  • 3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS
    申请人:GlaxoSmithKline Intellectual Property Development Limited
    公开号:EP3233844A1
    公开(公告)日:2017-10-25
  • Compounds exhibiting efflux inhibitor activity and composition and uses thereof
    申请人:Wempe Fitzpatrick Michael
    公开号:US20070254859A1
    公开(公告)日:2007-11-01
    At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
  • US9932328B2
    申请人:——
    公开号:US9932328B2
    公开(公告)日:2018-04-03
查看更多